Genetic manipulation of LKB1 elicits lethal metastatic prostate cancerIvana Heřmanová, Arkaitz Carracedo, Juana M. Flores et al.|The Journal of Experimental Medicine|2020Cited by 34
Elacestrant in Women with Estrogen Receptor–Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE TrialMaría Vidal, Meritxell Bellet, Claudette Falato et al.|Clinical Cancer Research|2025Cited by 7
Abstract OT2-11-07: Solti-1905. Elacestrant in preoperative setting, a window of opportunity study (ELIPSE trial)María Vidal, Meritxell Bellet, Montserrat Muñoz-Mateu et al.|Cancer Research|2022Cited by 4
Supplementary Figure S4 from Elacestrant in Women with Estrogen Receptor–Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE TrialMaría Vidal, Meritxell Bellet, Claudette Falato et al.|Unknown|2025Cited by 0
Supplementary Table S3 from Elacestrant in Women with Estrogen Receptor–Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE TrialMaría Vidal, Meritxell Bellet, Claudette Falato et al.|Unknown|2025Cited by 0